Skip to main content
Clinical Trials/NCT05598164
NCT05598164
Recruiting
N/A

Botulinum Toxin Type A in the Treatment of Chronic Anal Fissure Without Excision

State Scientific Centre of Coloproctology, Russian Federation1 site in 1 country140 target enrollmentSeptember 1, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
Chronic Anal Fissure
Sponsor
State Scientific Centre of Coloproctology, Russian Federation
Enrollment
140
Locations
1
Primary Endpoint
Anal sphincter insufficiency
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

This study is aimed at studying the effectiveness and safety of surgical treatment of chronic anal fissure.

Detailed Description

A chronic anal fissure is a rupture of the mucous membrane of the anal canal, lasting more than 2 months and resistant to non-surgical treatment. This condition is accompanied by a strong pain syndrome during and after defecation (defecation). This condition is most often found in young and able-bodied adults, so the issue of treatment is of particular relevance. The main cause of the development of a chronic anal fissure is a spasm of the internal sphincter. It should be eliminated first of all to ensure effective therapy. All the main treatment methods, such as medicinal relaxation of the internal sphincter with 0.4% nitroglycerin ointment, lateral subcutaneous sphincterotomy, and pneumodivulsion of the anal sphincter are aimed at its removal. However, the optimal method has not yet been developed. Non-surgical treatments are often attended by relapse of disease, while surgical treatment is often complicated by intestinal contents incontinence, usually gas and loose or hard stool in some occasions (grade 3 anal sphincter insufficiency). In particular, lateral subcutaneous sphincterotomy performed in such patients is associated with an increase in the degree of anal incontinence in the early post-operative period. Botulinum Toxin Type A application in treatment of patients with chronic anal fissure (after fissure excision) is intended to improve the therapy results, namely to reduce the frequency and duration of anal sphincter insufficiency after sphincter spasm removal (reduction in the number of patients suffering from post-operative incontinence).

Registry
clinicaltrials.gov
Start Date
September 1, 2022
End Date
May 1, 2025
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
State Scientific Centre of Coloproctology, Russian Federation
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients with chronic anal fissure with spasm of anal sphincter

Exclusion Criteria

  • Inflammatory diseases of the colon
  • Pectenosis
  • Previous surgical interventions on the anal canal
  • IV grade internal and external hemorrhoids
  • Rectal fistula
  • Severe somatic diseases at the decompensation stage
  • Pregnancy and lactation
  • Anal sphincter insufficiency
  • Chronic paraproctitis
  • Fibrous polyp of the anal canal, accompanied by clinical manifestations

Outcomes

Primary Outcomes

Anal sphincter insufficiency

Time Frame: Up to 60 days

Frequency of anal sphincter insufficiency according to the Wexner scale

Secondary Outcomes

  • 2-item pain intensity (P2)(On day 7, 30 and 60)
  • Profilometry /sphincterometry findings(On day 30, 60 and 365)
  • Relap(Up to 60 days)
  • Temporary disability(Up to 60 days)
  • Non-Healing Wound(On day 15, 30, 45, 60)

Study Sites (1)

Loading locations...

Similar Trials